> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Clears IsoRay’s GammaTile Brachytherapy
- URL: https://www.fdaweb.com/fda-clears-isorays-gammatile-brachytherapy/
- Published: 2018-07-09T12:00:00.000Z
- Updated: 2026-09-15T00:17:40.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5141823

FDA has cleared an IsoRay 510(k) for its GammaTile brachytherapy technology that uses proprietary Cesium-131 seeds within customizable collagen-based carriers for treating recurrent brain tumors. The therapy “leverages Cesium-131’s unique ability to deliver a highly targeted dose of intense radiation treatment while limiting radiation exposure to surrounding tissue,” the company says. The device was developed under a collaborative development agreement and an exclusive ten-year supply agreement with GT Medical Technologies.